Potential ↑ fentanyl concentrations. Due to the risk of clinically significant toxicity including respiratory depression, coadministration is not recommended.
Potential ↑ fentanyl concentration via CYP3A4 inhibition by ritonavir.
Pharmacokinetic study with ritonavir: In a healthy volunteer study, a 67% reduction in clearance and 174% increase in AUC of fentanyl was observed when IV fentanyl was coadministered with ritonavir 900 mg/day. Monitor for respiratory and CNS depression.1002
Significant interactions between transdermal fentanyl and CYP3A4 inhibitors including itraconazole, fluconazole, clarithromycin and lopinavir/ritonavir have been reported, with consequences including opioid toxicity, respiratory depression and/or death. These cases are described in more detail below.
Clarithromycin: an 81 year old male with dementia, COPD, cervical spondylosis and spinal stenosis received H. pylori treatment with clarithromycin and metronidazole while on fentanyl 200 ug/hour. Thirty-six hours after the antibiotics were started, he was unresponsive to verbal and tactile stimuli and was treated with naloxone. He was subsequently stabilized on fentanyl 100 ug/hour.2799
Fluconazole: a 46 year old man with tonsillar cancer was on fentanyl 150 ug/hour for pain control. Three weeks later, fluconazole 50 mg daily was started for oral candidiasis. The patient died 3 days later; toxic fentanyl concentrations (approximately 6-fold greater than the upper therapeutic range) were noted.2788
Itraconazole: a 67 year old male with head and neck cancer was on fentanyl 50 ug/hour. He started treatment with itraconazole 200 mg BID for oropharyngeal candidiasis. Signs and symptoms of opioid toxicity were noted the next day, and he was eventually stablized on fentanyl 25 ug/hour.2797
Lopinavir/ritonavir: a 46 year old female on fentanyl 100 ug/hour received HIV post-exposure prophylaxis with lopinavir/ritonavir and zidovudine/lamivudine. Four days later she was very drowsy and needed frequent wakening. She was found unresponsive later that night.2800
The Norvir (ritonavir) monograph states that careful monitoring of therapeutic and adverse effects (including respiratory depression) is recommended when ritonavir is co-administered with fentanyl, including extended release, transdermal or transmucosal preparations.899
The Duragesic MAT (fentanyl) monograph states that concomitant use of transdermal fentanyl and CYP3A4 inhibitors is not recommended unless the patient is monitored closely for signs of respiratory depression. Monitoring should be done for an extended period of time, with fentanyl dose adjustments as required.2801
Due to the risk of clinically significant outcomes (including respiratory depression), coadministration of fentanyl with CYP3A4 inhibitors including cobicistat or ritonavir is not recommended.
Lopinavir is a substrate and weak inhibitor of CYP3A4.
Potential for interactions with other enzyme inducers or inhibitors [see also Interactions with Ritonavir].
Once-daily dosing is NOT recommended in:
With efavirenz or nevirapine:
Ctrough 7.1 ± 2.9 ug/mL, Cmin 5.5 ± 2.7 ug/mL, AUC 92.6 ± 36.7 ug.h/mL
Body weight is a significant predictor of lopinavir kinetics (AUC, Cmax); subjects with lower body weight tend to have higher lopinavir Cmax and AUC [Bertz 2001]
In vivo intracellular accumulation: cell/plasma ratio 0.65-1.55 when dosed with ritonavir.
23 Thai HIV infected children (age 2-18 years) were randomized to standard dose of LPV (according to WHO dosing table) or low dose of LPV (70% of recommended dose); NRTI backbone was AZT + 3TC, kinetic study done at 4-6 weeks.
LPV/r standard dose N = 11 | LPV/r low dose N =12 | |
Median dose | 288 mg/m2 BID | 194 mg/m2 BID |
Mean AUC 0-12hr | 107.1 h.mg/L | 84.6 h.mg/L |
Mean Cmax | 11.9 mg/L | 9.8 mg/L |
Mean Cmin | 5.2 mg/L | 3.8 mg/L |
1 child in low dose group had subtherapeutic LPV/r concentration (< 1mg/L). There was no statistical difference in CD4 and VL between the groups (van Der Lugt et al. 2008).
Comparison of lopinavir and ritonavir tablet and soft gelatin capsule (SGC) pharmacokinetics in antiretroviral naive HIV-1 infected subjects:
Fixed-dose combination tablets of lopinavir/ritonavir/lamivudine or lopinavir/ritonavir/lamivudine/zidovudine shown to be bioequivalent to the individual marketed products under fasting conditions. The food effect on both fixed-dose combinations is similar to that of the marketed products. [Salem et al. 2014 IWCPHT]
Substrate of CYP3A4. Intestinal p-gp plays a role in the absorption of oral fentanyl.
Note: The web app has been optimized for the following browsers: Google Chrome, Apple Safari. Other web browsers (e.g. Mozilla Firefox, Internet Explorer, Opera, etc) may experience performance issues. Please use one of the optimized browser versions, or download our mobile application.
The information in this website/app is intended for use by and with experienced physicians and pharmacists. The information is not intended to replace sound professional judgment in individual situations, and should be used in conjunction with other reliable sources of information. Due to the rapidly changing nature of information about HIV treatment and therapies, users are advised to recheck the information contained herein with the original source before applying it to patient care. Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV-related illness and the treatments in question.
Neither Toronto General Hospital, Alberta Health Services, the Ottawa Hospital, nor the authors and contributors are responsible for deletions or inaccuracies in information or for claims of injury resulting from any such deletions or inaccuracies. Mention of specific drugs, drug doses or drug combinations within this website does not constitute endorsement by the authors, Toronto General Hospital, Alberta Health Services or the Ottawa Hospital.
The opinions expressed herein are those of its authors and do not necessarily reflect the views and opinions of Abbvie, Gilead Canada, Merck Canada Inc., and ViiV Healthcare.
We emphasize that program only checks for interactions between HIV or HCV drugs and other drugs, it will NOT check for interactions between sets of non-HIV or HCV drugs.
Also, program content focuses primarily on pharmacokinetic based interactions, and will not include comprehensive data on pharmacodynamics interactions, including QT prolongation.
Last updated: January 10, 2016
Please read these Terms, Conditions & Disclaimer carefully before using the www.hivclinic.ca website (the "Service") operated by Immunodeficiency Clinic ("us", "we", or "our").
By using this site, you signify your assent to these Terms and Conditions. If you do not agree to all of these Terms and Conditions of use, do not use this site. The Immunodeficiency Clinic may revise and update these Terms and Conditions without notice at any time. Your continued usage of the Immunodeficiency Clinic Web site (the "site") will mean you accept those changes.
Any Web sites linked from the site are created by organizations outside the Immunodeficiency Clinic. Those organizations are responsible for the information contained within their sites. We do not recommend and do not endorse the content on any third-party websites. We are not responsible for the content of linked third-party sites or third-party advertisements and do not make any representations regarding their content or accuracy. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites. Any specific comments regarding these sites should be directed to that individual organization.
These Terms shall be governed and construed in accordance with the laws of Ontario, Canada, without regard to its conflict of law provisions. Our failure to enforce any right or provision of these Terms will not be considered a waiver of those rights. If any provision of these Terms is held to be invalid or unenforceable by a court, the remaining provisions of these Terms will remain in effect. These Terms constitute the entire agreement between us regarding our Service, and supersede and replace any prior agreements we might have between us regarding the Service.
We reserve the right, at our sole discretion, to modify or replace these Terms at any time. If a revision is material we will try to provide at least 30 days notice prior to any new terms taking effect. What constitutes a material change will be determined at our sole discretion. By continuing to access or use our Service after those revisions become effective, you agree to be bound by the revised terms. If you do not agree to the new terms, please stop using the Service.
Thank you for visiting the HIV/HCV Drug Therapy Guide housed on the Toronto General Hospital Immunodeficiency Clinic Web site. General aggregate user data that will be tracked for both the web-based and mobile applications includes country of origin, new vs. returning visitor to the site, browsers used and sections of the guide that are used most frequently. Any identifying personal information will not be collected.
Accessing information from the HIV/HCV Drug Therapy Guide: This web-based application is housed on the Toronto General Hospital Immunodeficiency Clinic Web site at app.hivclinic.ca. Future updates will include an application for mobile devices also.
The Toronto General Hospital website has been in operation since 2000. The main objectives of the drug information portion of the website/app are to provide a comprehensive and centralized repository of current data on HIV/HCV drug therapy for health care professionals with a main focus on drug interactions, and to promote safe and rational prescribing of antiretrovirals and directly acting antivirals. The website/app content is updated regularly, and includes information from key international HIV/HCV conferences and recent publications in the medical/pharmacy literature.
The primary editors of the website/app content are:
The ongoing contributions of Michelle Foisy, PharmD, founding co-editor, as well as the following people are also gratefully acknowledged: Michelle Bender, Alison Wong, Bill Cornish, Margaret Ackman, Tony Antoniou, Cara Hills-Nieminen, Natalie Dayneka, Dominic Martel, Denise Kreutzwiser, Cherry Hui, Sanjeev Sockalingham.
Contact us at: app@hivclinic.ca
HIV/HCV Drug Therapy Guide. UHN- Toronto General Hospital, Immunodeficiency Clinic; 2022 [insert date cited e.g. cited 2022 Jan 10]. Available from: https://app.hivclinic.ca/
Thank you for visiting. We hope you find your visit to be worthwhile and useful.
Please select below to enable or disable visible sections for print output. Your printout will also depend on what you have opened on the screen when you click the print button.